Lack of prognostic significance of serum DNA methylation of DAPK, MGMT, and GSTPI in patients with non-small cell lung cancer.

A C Hoffmann; Jussuf Kaifi; D Vallböhmer; Emre F. Yekebas; P Grimminger; J M Leers; Jakob R. Izbicki; A H Hölscher; P M Schneider; R Metzger; J Brabender

Lack of prognostic significance of serum DNA methylation of DAPK, MGMT, and GSTPI in patients with non-small cell lung cancer.

Standard

Lack of prognostic significance of serum DNA methylation of DAPK, MGMT, and GSTPI in patients with non-small cell lung cancer. / Hoffmann, A C; Kaifi, Jussuf; Vallböhmer, D; Yekebas, Emre F.; Grimminger, P; Leers, J M; Izbicki, Jakob R.; Hölscher, A H; Schneider, P M; Metzger, R; Brabender, J.

In: J SURG ONCOL, Vol. 100, No. 5, 5, 2009, p. 414-417.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Hoffmann, AC, Kaifi, J, Vallböhmer, D, Yekebas, EF, Grimminger, P, Leers, JM, Izbicki, JR, Hölscher, AH, Schneider, PM, Metzger, R & Brabender, J 2009, 'Lack of prognostic significance of serum DNA methylation of DAPK, MGMT, and GSTPI in patients with non-small cell lung cancer.', J SURG ONCOL, vol. 100, no. 5, 5, pp. 414-417. <http://www.ncbi.nlm.nih.gov/pubmed/19653236?dopt=Citation>

APA

Hoffmann, A. C., Kaifi, J., Vallböhmer, D., Yekebas, E. F., Grimminger, P., Leers, J. M., Izbicki, J. R., Hölscher, A. H., Schneider, P. M., Metzger, R., & Brabender, J. (2009). Lack of prognostic significance of serum DNA methylation of DAPK, MGMT, and GSTPI in patients with non-small cell lung cancer. J SURG ONCOL, 100(5), 414-417. [5]. http://www.ncbi.nlm.nih.gov/pubmed/19653236?dopt=Citation

Vancouver

Hoffmann AC, Kaifi J, Vallböhmer D, Yekebas EF, Grimminger P, Leers JM et al. Lack of prognostic significance of serum DNA methylation of DAPK, MGMT, and GSTPI in patients with non-small cell lung cancer. J SURG ONCOL. 2009;100(5):414-417. 5.

Bibtex

@article{c1745332b64f461699afdffff2e4ee31,

title = "Lack of prognostic significance of serum DNA methylation of DAPK, MGMT, and GSTPI in patients with non-small cell lung cancer.",

abstract = "BACKGROUND AND OBJECTIVES: To further improve the screening, diagnosis and therapy of patients with non-small cell lung cancer (NSCLC) additional diagnostic tools are desperately warranted. Aim of this study was to investigate the potential of the DNA methylation of DAPK, MGMT, and GSTPI in serum of patients with NSCLC as a prognostic molecular marker in this disease. METHODS: Seventy-six patients with NSCLC were included in this study. The analysis of DNA methylation in serum of patients was performed on pre-operative samples. Following DNA isolation and bisulfite-treatment, DNA methylation was analyzed by quantitative-methylation-specific real-time PCR with beta-actin as the internal reference gene. RESULTS: DNA methylation was detectable with following frequencies: DAPK 68.4%, MGMT 7.9%, GSTPI 0%. There were no associations between DNA methylation status and histology, tumor stage, grading or gender detectable. With a mean follow-up of 19.7 months the median survival was 26.3 months. There were no associations between the status of DNA methylation in patient's serum and prognosis detectable. CONCLUSION: The analysis of DNA methylation in serum of patients with NSCLC by quantitative-methylation-specific real-time PCR is technically feasible. Although our results suggest quantification of DNA methylation in serum not of prognostic significance in this disease, further studies are warranted to determine the future potential of this molecular approach.",

author = "Hoffmann, {A C} and Jussuf Kaifi and D Vallb{\"o}hmer and Yekebas, {Emre F.} and P Grimminger and Leers, {J M} and Izbicki, {Jakob R.} and H{\"o}lscher, {A H} and Schneider, {P M} and R Metzger and J Brabender",

year = "2009",

language = "Deutsch",

volume = "100",

pages = "414--417",

journal = "J SURG ONCOL",

issn = "0022-4790",

publisher = "Wiley-Liss Inc.",

number = "5",

}

RIS

TY - JOUR

T1 - Lack of prognostic significance of serum DNA methylation of DAPK, MGMT, and GSTPI in patients with non-small cell lung cancer.

AU - Hoffmann, A C

AU - Kaifi, Jussuf

AU - Vallböhmer, D

AU - Yekebas, Emre F.

AU - Grimminger, P

AU - Leers, J M

AU - Izbicki, Jakob R.

AU - Hölscher, A H

AU - Schneider, P M

AU - Metzger, R

AU - Brabender, J

PY - 2009

Y1 - 2009

N2 - BACKGROUND AND OBJECTIVES: To further improve the screening, diagnosis and therapy of patients with non-small cell lung cancer (NSCLC) additional diagnostic tools are desperately warranted. Aim of this study was to investigate the potential of the DNA methylation of DAPK, MGMT, and GSTPI in serum of patients with NSCLC as a prognostic molecular marker in this disease. METHODS: Seventy-six patients with NSCLC were included in this study. The analysis of DNA methylation in serum of patients was performed on pre-operative samples. Following DNA isolation and bisulfite-treatment, DNA methylation was analyzed by quantitative-methylation-specific real-time PCR with beta-actin as the internal reference gene. RESULTS: DNA methylation was detectable with following frequencies: DAPK 68.4%, MGMT 7.9%, GSTPI 0%. There were no associations between DNA methylation status and histology, tumor stage, grading or gender detectable. With a mean follow-up of 19.7 months the median survival was 26.3 months. There were no associations between the status of DNA methylation in patient's serum and prognosis detectable. CONCLUSION: The analysis of DNA methylation in serum of patients with NSCLC by quantitative-methylation-specific real-time PCR is technically feasible. Although our results suggest quantification of DNA methylation in serum not of prognostic significance in this disease, further studies are warranted to determine the future potential of this molecular approach.

AB - BACKGROUND AND OBJECTIVES: To further improve the screening, diagnosis and therapy of patients with non-small cell lung cancer (NSCLC) additional diagnostic tools are desperately warranted. Aim of this study was to investigate the potential of the DNA methylation of DAPK, MGMT, and GSTPI in serum of patients with NSCLC as a prognostic molecular marker in this disease. METHODS: Seventy-six patients with NSCLC were included in this study. The analysis of DNA methylation in serum of patients was performed on pre-operative samples. Following DNA isolation and bisulfite-treatment, DNA methylation was analyzed by quantitative-methylation-specific real-time PCR with beta-actin as the internal reference gene. RESULTS: DNA methylation was detectable with following frequencies: DAPK 68.4%, MGMT 7.9%, GSTPI 0%. There were no associations between DNA methylation status and histology, tumor stage, grading or gender detectable. With a mean follow-up of 19.7 months the median survival was 26.3 months. There were no associations between the status of DNA methylation in patient's serum and prognosis detectable. CONCLUSION: The analysis of DNA methylation in serum of patients with NSCLC by quantitative-methylation-specific real-time PCR is technically feasible. Although our results suggest quantification of DNA methylation in serum not of prognostic significance in this disease, further studies are warranted to determine the future potential of this molecular approach.

M3 - SCORING: Zeitschriftenaufsatz

VL - 100

SP - 414

EP - 417

JO - J SURG ONCOL

JF - J SURG ONCOL

SN - 0022-4790

IS - 5

M1 - 5

ER -